PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients

• Published in: Journal of pediatric gastroenterology and nutrition Vol. 76; no. 4; pp. 451 - 459
• Main Authors: Martinez-Vinson, Christine, Lemoine, Anaïs, Bouhnik, Yoram, Braithwaite, Ben, Fohlen-Weill, Audrey, Addison, Janet
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 01-04-2023
• Subjects: Antibodies, Monoclonal - therapeutic use; Biosimilar Pharmaceuticals - therapeutic use; Child; Cohort Studies; Colitis, Ulcerative - drug therapy; Crohn Disease - drug therapy; Gastrointestinal Agents - therapeutic use; Humans; Inflammatory Bowel Diseases - drug therapy; Infliximab - therapeutic use; Original : Gastroenterology: Inflammatory Bowel Disease; Remission Induction; Treatment Outcome
• ISSN: 0277-2116; 1536-4801
• DOI: 10.1097/MPG.0000000000003683

PERFUSE is a non-interventional study of 1233 patients [inflammatory rheumatic disease, n = 496; inflammatory bowel disease (IBD), n = 737] receiving infliximab (IFX) biosimilar SB2 therapy. This analysis describes response to treatment and persistence on SB2 for up to 12 months in pediatric IBD patients (n = 126).
Pediatric IBD patients with Crohn disease (CD) or ulcerative colitis (UC), either naïve or switched from originator IFX, who started SB2 in routine practice after September 2017 were eligible. Data were captured for 12 months following SB2 initiation. Disease activity was measured using C-reactive protein (CRP) levels and the Harvey-Bradshaw Index or Pediatric Ulcerative Colitis Activity Index for CD and UC patients, respectively. Body mass index and height z scores were used to assess patient growth between initiation (M0) and month 12 (M12).
One hundred twenty-six pediatric IBD patients were included (102 CD patients, 51 naïve and 51 switched; 24 UC patients, 9 naïve and 15 switched). Naive patients' disease scores decreased between M0 and M12. CRP measurements also decreased in naïve CD patients. Switched patients' disease scores and CRP levels remained stable between M0 and M12. Height z scores improved significantly over the course of the treatment for all groups except for naïve UC patients.
SB2 provides effective disease control for naïve and switched pediatric patients. Clinical remission rates improved in naïve patients and no loss of control was observed in switched patients after 1 year. Growth failure is not observed in IBD patients under SB2 treatment.